DNA methylation markers predict outcome in node-positive, Estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 315-323

  Hartmann, Oliver ^a   Spyratos, Frédérique ^d   Harbeck, Nadia ^b   Dietrich, Dimo ^a   Fassbender, Anne ^a   Schmitt, Manfred ^b   Eppenberger Castori, Serenella ^c   VincentVuaroqueaux, ^c   Lerebours, Florence ^d   Welzel, Katrin ^a   Maier, Sabine ^a   Plum, Achim ^a   Niemann, Stephan ^a   Foekens, John A ^e   Lesche, Ralf ^a   Martens, John W M ^e  

^a EPIGENOMICS AG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Stiftung Tumorbank Basel   (Switzerland)

^d Centre René   (France)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BONE MORPHOGENETIC PROTEIN 4; BRCA1 PROTEIN; DNA MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 4; PROTEIN; REGULATOR PROTEIN; TRANSCRIPTION FACTOR PITX2;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DNA METHYLATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTHRACYCLINES; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA METHYLATION; FEMALE; GENES, ERBB-2; HOMEODOMAIN PROTEINS; HUMANS; LYMPHATIC METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTORS, ESTROGEN; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 58849143465     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0166     Document Type: Article

References (45)

1. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 2007; 18:1133-44.
2. Jones S, Holmes F, O'Shaughnessy J, et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/ cyclophosphamide is associated with an overall survival benefit compared to doxorubicin /cyclophosphamide and is well-tolerated in women 65 or older. San Antonio Breast Cancer Meeting 2007.
3. Piccart-Gebhart MJ. Anthracyclines and the tailoring of treatment for early breast cancer. N Engl J Med 2006; 354:2177-9.
4. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16:168-74.
5. Jones PA. DNA methylation errors and cancer. Cancer Res 1996; 56:2463-7.
6. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042-54.
7. Adorjan P, Distler J, Lipscher E, et al. Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res 2002; 30:e21.
8. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350-4.
9. Esteller M, Gaidano G, Goodman SN, et al. Hypermethylation of the DNA repair gene O (6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 2002; 94:26-32.
10. Fruhwald MC. DNA methylation patterns in cancer: novel prognostic indicators? Am J Pharmacogenomics 2003; 3:245-60.
11. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3:253-66.
12. Yang H, Chen CM, Yan P, et al. The androgen receptor gene is preferentially hypermethylated in follicular non-Hodgkin's lymphomas. Clin Cancer Res 2003; 9: 4034-42.
13. Maier S, Nimmrich I, KoenigT, et al. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients-technical and clinical validation in a multicentre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group. Eur J Cancer 2007; 43: 1679-86.
14. Martens JWM, Nimmrich I. KoenigT, et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005; 65:4101-17.
15. Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, et al. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer ResTreat 2008; 111:429-37.
16. Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004; 64:3807-13.
17. Harbeck N, Nimmrich I, Hartmann A, et al. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 2008; 26:5036-42.
18. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002; 18 Suppl 1: S96-104.
19. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall; 1984.
20. Harrell FE. Regression modeling strategies. New York: Springer: 2001.
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
22. Harrell FE, Jr., Califf RM, Pryor DB, Lee KL, Rosati RA, Evaluating the yield of medical tests. JAMA 1982; 247:2543-6.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289-300
24. Molinaro AM, Simon R, Pfeiffer RM Prediction error estimation: a comparison of resampling methods Bioinformatics 2005; 21:3301-7.
25. Barrier A, Roser F, Boelle PY, et al. Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 2007; 26:2642-8
26. Pritchard Kl, Shepherd LE, O'Malley FP. et al. HER 2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354:2103-11
27. Altman DG, Lyman GH Methodological challenges in the evaluation of prognostic factors in breast cancer Breast Cancer Res Treat 1998;52:289-303
28. Levine MN, Bramwell V, Pritchard K, et al. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer Eur J Cancer 1992; 29A37-43.
29. Martin M. Pienkowski T, Mackey J. et al. Adjuvant docetaxel for node-positive breast cancer N Engl J Med 2005; 352:2302-13.
30. Kummel S, Rezai M, Kimmig R. Schmid P. Dose dense chemotherapy for primary breast cancer. Curr Opin Obstet Gynecol 2007; 19:75-81
31. Paz MF, Wei S. Cigudosa JC, et al Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases Hum Mol Genet 2003; 12:2209-19
32. WangY, Yu Q, Cho AH, et al. Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 2005; 7:748-60.
33. RauchT, Li H. Wu X, Pfeifer GP. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-contaning genes in lung cancer cells Cancer Res 2006;66 7939-47
34. Evron E, Umbricht CB, Korz D, et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001; 61:2782-7.
35. Rosenbaum E, Hoque MO, Cohen Y, et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005; 11:8321-5.
36. Sakuma M, Akahira J, Ito K, et al. Promoter methylation status of the cyclin D2 gene is associated with poor prognosis in human epithelial ovarian cancer. Cancer Sci 2007; 98:380-6.
37. Egawa C, Motomura K, Miyoshi Y, et al. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. Breast Cancer Res Treat 2003; 78:45-50.
38. Look MP, van Putten WLJ, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94:116-28.
39. Guo Y, Pakneshan P, Gladu J, Slack A, Szyf M, Rabbani SA. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J Biol Chem 2002; 277:41571-9.
40. Pakneshan P, Szyf M, Rabbani SA. Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Curr Cancer Drug Targets 2005; 5:471-88.
41. Pakneshan P,Tetu B, Rabbani SA. Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin Cancer Res 2004; 10: 3035-41.
42. Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase- type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002; 62:4617-22.
43. Hauge H, Patzke S, Aasheim HC. Characterization of the FAM110 gene family. Genomics 2007; 90:14-27.
44. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369:559-70.
45. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-2.